Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Affymax, a biopharmaceutical company engaged in developing novel drugs to improve the treatment of serious and often life-threatening conditions, has posted total revenues of $112.52m for the full year ended 31 December 2010, compared to $114.9m for the same period in 2009.
Subscribe to our email newsletter
The company’s loss from operations was $14.45m for the full year ended 31 December 2010, compared to $78.94m for the same period in 2009.
Affymax has generated net loss of $14.08m for the full year of 2010, compared to net loss of $76.53m for the same period in 2009.
Affymax CEO John Orwin said looking at planned activities in 2011, their highest priority is to submit the New Drug Application for Peginesatide to the FDA in the second quarter.
"In addition, we will continue laying the groundwork for potential approval and launch of the product, including preparing for pre-approval inspections, getting ready for a potential FDA advisory committee review, and initiating a Phase 3b program designed to evaluate the process and outcomes of converting dialysis centers from a three times a week ESA to a once monthly ESA," Orwin said.